Chief Accounting Officer
Bio-Rad Laboratories, Inc. (BIO)Equibles does not estimate personal net worth.
Get an email with a short summary when Bio-Rad Laboratories, Inc. publishes a filing, an earnings call transcript or a press release.
Get BIO alertsRoop K. Lakkaraju is recorded as Chief Accounting Officer at Bio-Rad Laboratories, Inc. (BIO) since April 26, 2024 and CFO at Bio-Rad Laboratories, Inc. (BIO) since April 15, 2024. The newest filing on record that lists Roop K. Lakkaraju as CFO at Bio-Rad Laboratories, Inc. (BIO) is dated March 25, 2026. Bio-Rad Laboratories, Inc. reported in an 8-K filed April 26, 2024 that Roop K. Lakkaraju was appointed principal accounting officer, effective April 26, 2024. Bio-Rad Laboratories, Inc. reported in an 8-K filed March 20, 2024 that Roop K. Lakkaraju was appointed Executive Vice President, Chief Financial Officer, effective April 15, 2024. Benchmark Electronics Inc reported in an 8-K filed March 19, 2024 that Roop K. Lakkaraju resigned as Executive Vice President and Chief Financial Officer ("CFO") and Principal Accounting Officer ("PAO"), effective April 1, 2024. The proxy statement of Bio-Rad Laboratories, Inc. reports total compensation of $2,990,738 for Roop K. Lakkaraju in fiscal 2025, including a base salary of $629,100. Disclosed compensation is on record for 2 fiscal years. Roop K. Lakkaraju has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Bio-Rad Laboratories, Inc. on June 3, 2026. Bio-Rad Laboratories, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Bio-Rad Laboratories, Inc. includes Norman Schwartz (CEO, CFO and Board Member), Roop Lakkaraju (CFO), Jonathan DiVincenzo (COO) and 7 others.
“On April 26, 2024, the Company disclosed that Roop K. Lakkaraju, the Company’s Executive Vice President and Chief Financial Officer (and principal financial officer) will act as the Company’s principal accounting officer.”
“On March 20, 2024, Bio-Rad Laboratories, Inc. (the “Company”) announced the appointment by the Board of Directors of the Company of Roop K. Lakkaraju as the Company’s Executive Vice President, Chief Financial Officer (including as principal financial officer), effective April 15, 2024.”
“So I've been with the company for about two years now, and it's been a lot of change. And part of that change is me coming on board, but also other new leadership that's come on board over the past couple of years, 18 to 24 months, let's call it.”
“I'd like to start with a review of the second quarter 2025 results. Overall, we executed well during the quarter. Net sales for the second quarter of 2025 were approximately $652 million, which represents a 2.1% increase on a reported basis versus $638 million in Q2 of 2024.”
“I'd like to start with a review of the fourth quarter of full year 2024 results net sales for the fourth quarter of 2024 were approximately 668 million which represents a two percent decline on a reported basis versus 681 million in q4 of 2023 on a currency neutral basis this represents a 2.3 percent year-over-year…”
2024-04-26–present
2024-04-15–present
Last confirmed March 25, 2026
Medical Devices · Healthcare
Chief Accounting Officer, CFO
2024-04-15–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bio-Rad Laboratories, Inc. (BIO) | Executive Vice President, Chief Financial Officer | $629,100 | $2,990,738 |
| 2024 | Bio-Rad Laboratories, Inc. (BIO) | Executive Vice President, Chief Financial Officer | $426,923 | $3,775,075 |
